134 related articles for article (PubMed ID: 35660381)
21. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures.
Proctor DM; Suh M; Campleman SL; Thompson CM
Toxicology; 2014 Nov; 325():160-79. PubMed ID: 25174529
[TBL] [Abstract][Full Text] [Related]
22. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling and bioinformatics analysis in 16HBE cells treated by chromium (VI).
Hu G; Liu J; Zhang Y; Zheng P; Wang L; Zhao L; Xu H; Chen Z; Wang T; Jia G
Toxicol Lett; 2016 Dec; 264():71-78. PubMed ID: 27793765
[TBL] [Abstract][Full Text] [Related]
24. β
Zhang M; Wang Q; Sun X; Yin Q; Chen J; Xu L; Xu C
Prostate; 2020 Nov; 80(15):1328-1340. PubMed ID: 32894788
[TBL] [Abstract][Full Text] [Related]
25. Cancer germline antigen gene MAGEB2 promotes cell invasion and correlates with immune microenvironment and immunotherapeutic efficiency in laryngeal cancer.
Cui J; Chen Y; Ou Y; Liu G; Wen Q; Zhu W; Liang L; Chen Z; Yang H; Wang L; Wei M
Clin Immunol; 2022 Jul; 240():109045. PubMed ID: 35618211
[TBL] [Abstract][Full Text] [Related]
26. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades.
Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z
Life Sci; 2020 May; 248():117449. PubMed ID: 32088212
[TBL] [Abstract][Full Text] [Related]
27. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
28. Targeting the unique methylation pattern of androgen receptor (AR) promoter in prostate stem/progenitor cells with 5-aza-2'-deoxycytidine (5-AZA) leads to suppressed prostate tumorigenesis.
Tian J; Lee SO; Liang L; Luo J; Huang CK; Li L; Niu Y; Chang C
J Biol Chem; 2012 Nov; 287(47):39954-66. PubMed ID: 23012352
[TBL] [Abstract][Full Text] [Related]
29. Hexavalent chromium induces energy metabolism disturbance and p53-dependent cell cycle arrest via reactive oxygen species in L-02 hepatocytes.
Xiao F; Feng X; Zeng M; Guan L; Hu Q; Zhong C
Mol Cell Biochem; 2012 Dec; 371(1-2):65-76. PubMed ID: 22886373
[TBL] [Abstract][Full Text] [Related]
30. Is hexavalent chromium carcinogenic via ingestion? A weight-of-evidence review.
Proctor DM; Otani JM; Finley BL; Paustenbach DJ; Bland JA; Speizer N; Sargent EV
J Toxicol Environ Health A; 2002 May; 65(10):701-46. PubMed ID: 12028825
[TBL] [Abstract][Full Text] [Related]
31. LncRNA expression profiling and its relationship with DNA damage in Cr(VI)-treated 16HBE cells.
Hu G; Feng H; Long C; Zhou D; Li P; Gao X; Chen Z; Wang T; Jia G
Sci Total Environ; 2019 Mar; 655():622-632. PubMed ID: 30476843
[TBL] [Abstract][Full Text] [Related]
32. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
33. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
34. Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1.
Nobeyama Y; Nakagawa H
J Dermatol Sci; 2016 Feb; 81(2):118-23. PubMed ID: 26642794
[TBL] [Abstract][Full Text] [Related]
35. Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.
Asim M; Hafeez BB; Siddiqui IA; Gerlach C; Patz M; Mukhtar H; Baniahmad A
J Biol Chem; 2011 Oct; 286(43):37108-17. PubMed ID: 21856747
[TBL] [Abstract][Full Text] [Related]
36. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
37. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
38. Chromium IV exposure, via Src/Ras signaling, promotes cell transformation.
Ganapathy S; Li P; Lafontant J; Xiong R; Yu T; Zhang G; Chen C
Mol Carcinog; 2017 Jul; 56(7):1808-1815. PubMed ID: 28218450
[TBL] [Abstract][Full Text] [Related]
39. The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer.
Lim SC; Geleta B; Maleki S; Richardson DR; Kovačević Ž
J Biol Chem; 2021 Dec; 297(6):101414. PubMed ID: 34785213
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
